FR10C0016I1 - - Google Patents

Info

Publication number
FR10C0016I1
FR10C0016I1 FR10C0016C FR10C0016I1 FR 10C0016 I1 FR10C0016 I1 FR 10C0016I1 FR 10C0016 C FR10C0016 C FR 10C0016C FR 10C0016 I1 FR10C0016 I1 FR 10C0016I1
Authority
FR
France
Prior art keywords
antibodies
therapeutic uses
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22888581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR10C0016I1 publication Critical patent/FR10C0016I1/fr
Application granted granted Critical
Publication of FR10C0016I2 publication Critical patent/FR10C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)

Abstract

Anti-C5 antibodies and their therapeutic uses.
FR10C0016C 1994-05-02 2010-03-19 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS Active FR10C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/236,208 US6074642A (en) 1994-05-02 1994-05-02 Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PCT/US1995/005688 WO1995029697A1 (en) 1994-05-02 1995-05-01 Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases

Publications (2)

Publication Number Publication Date
FR10C0016I1 true FR10C0016I1 (en) 2010-04-30
FR10C0016I2 FR10C0016I2 (en) 2011-04-01

Family

ID=22888581

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0016C Active FR10C0016I2 (en) 1994-05-02 2010-03-19 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS

Country Status (15)

Country Link
US (2) US6074642A (en)
EP (5) EP2112165A3 (en)
JP (5) JP3734266B2 (en)
KR (2) KR100442019B1 (en)
AT (1) ATE448791T1 (en)
AU (1) AU2474795A (en)
BR (1) BR9507594B8 (en)
CA (2) CA2189015C (en)
DE (2) DE122009000075I1 (en)
DK (1) DK0758904T3 (en)
ES (1) ES2336051T3 (en)
FR (1) FR10C0016I2 (en)
NL (1) NL300433I2 (en)
PT (1) PT758904E (en)
WO (1) WO1995029697A1 (en)

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
WO1996009043A1 (en) * 1994-09-23 1996-03-28 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
AU762050B2 (en) 1998-02-20 2003-06-19 Genentech, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
DE19913707A1 (en) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunosorbent for sepsis therapy
JP2003504019A (en) * 1999-06-29 2003-02-04 オートゲン リサーチ プロプライエトリー リミティッド Novel genes and their use in regulating obesity, diabetes and energy imbalance
EP1287364B1 (en) 2000-04-29 2008-10-22 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP2113516B1 (en) * 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
ES2283594T5 (en) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibitors of the complement pathway that bind to C5 and C5a without preventing the formation of C5b
EP1461428B1 (en) 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Method for producing hybrid antibodies
US20050221382A1 (en) * 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
ITMI20021527A1 (en) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20090010937A1 (en) * 2004-01-28 2009-01-08 Chauhan Anil K Membrane Attack Complexes Associated with Circulating Immune Complexes
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005110481A2 (en) 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
RU2445975C2 (en) 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Prolongation of allograft survival by complement activity inhibition
PT1991275E (en) 2006-03-08 2015-02-03 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
AU2006343402A1 (en) * 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
EP2826788B1 (en) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
NZ575018A (en) * 2006-09-05 2012-04-27 Alexion Pharma Inc Compositions for the treatment of antibody mediated neuropathies
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
WO2008048689A2 (en) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
KR20160092061A (en) 2006-11-02 2016-08-03 제넨테크, 인크. Humanized anti-factor d antibodies
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
BRPI0809105A2 (en) * 2007-03-22 2019-09-10 Novartis Ag c5 antigens and use of these
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2185594B1 (en) * 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
NO2708559T3 (en) 2008-04-11 2018-08-25
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
EP2280928B1 (en) * 2008-05-01 2018-07-25 Complexa Inc. Vinyl substituted fatty acids
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
DK2379066T3 (en) 2008-09-16 2014-06-30 Imunek Farma Ilaç Sanayi Ve Ticaret A S APPLICATION OF OPIOID ANTAGONISTS FOR THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF RETAINED DEGENERY DISEASES
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN109045296A (en) 2008-11-10 2018-12-21 阿雷克森制药公司 For treating the method and composition of complement associated disorders
PL2881402T3 (en) 2009-02-12 2017-10-31 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
ES2738700T3 (en) 2009-02-13 2020-01-24 Immunomedics Inc Immunoconjugates with an intracellularly cleavable link
NZ594638A (en) 2009-02-24 2013-03-28 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides for treatment of thrombocytopenia type conditions
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
JP2012531418A (en) * 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド Bispecific antibodies that bind complement proteins
US9066925B2 (en) 2009-07-02 2015-06-30 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011040894A1 (en) * 2009-10-01 2011-04-07 Mustafa Nevzat Ilaç Sanayii A.Ş. Topical compositions of opioid antagonists and methods for treating skin conditions therewith
KR20120130748A (en) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
SG183541A1 (en) * 2010-03-01 2012-10-30 Alexion Pharma Inc Methods and compositions for treating degos' disease
TWI667346B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
TR201002473A2 (en) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. A method of treating herpes zoster disease using an opiate receptor antagonist.
MX2012012689A (en) * 2010-04-30 2013-12-16 Alexion Pharma Inc Antibodies having reduced immunogenicity in a human.
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
KR20130036276A (en) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Antibodies to the c3d fragment of complement component 3
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
DE19177059T1 (en) 2010-10-01 2021-10-07 Modernatx, Inc. RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
KR20200103845A (en) 2011-02-25 2020-09-02 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
JP5838486B2 (en) 2011-04-15 2016-01-06 ソウル大学校産学協力団Ｓｎｕ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ Complex comprising anti-cotinine antibody bound to conjugate of conjugate substance and cotinine and use thereof
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
LT3682905T (en) 2011-10-03 2022-02-25 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104080909A (en) 2011-11-30 2014-10-01 中外制药株式会社 Drug containing carrier into cell for forming immune complex
PL2791160T3 (en) 2011-12-16 2022-06-20 Modernatx, Inc. Modified mrna compositions
CN106831985A (en) 2011-12-21 2017-06-13 诺华股份有限公司 The composition and method of the P factors are targeted for antibody
LT2817329T (en) 2012-02-20 2019-04-10 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
IN2014KN02324A (en) 2012-04-06 2015-05-01 Omeros Corp
ES2655842T3 (en) 2012-04-18 2018-02-21 Cell Signaling Technology, Inc. EGFR and ROS1 in cancer
CN104717975A (en) 2012-06-18 2015-06-17 奥默罗斯公司 Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JP2015535212A (en) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
KR102273985B1 (en) 2012-08-24 2021-07-06 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc region variant
TW201418707A (en) * 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists
RS63237B1 (en) 2012-11-26 2022-06-30 Modernatx Inc Terminally modified rna
HRP20220399T1 (en) 2012-12-13 2022-05-13 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
KR101638931B1 (en) * 2013-01-31 2016-07-12 서울대학교산학협력단 C5 antibodies and methods for the prevention and treatment of complement-associated disease
LT2970974T (en) 2013-03-14 2017-12-11 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
PE20151893A1 (en) 2013-03-14 2015-12-30 Parkash Gill TREATMENT OF CANCER USING ANTIBODIES THAT BIND GRP78 ON THE CELLULAR SURFACE
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2978451B1 (en) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR102318483B1 (en) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Fc region variant
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
CR20160132A (en) 2013-08-12 2016-08-25 Genentech Inc COMPOSITIONS AND METHOD TO TREAT CONDITIONS ASSOCIATED WITH THE COMPLEMENT
EP3033093A1 (en) * 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
NZ718153A (en) 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5
LT3039033T (en) 2013-08-28 2019-10-25 Affibody Ab Binding polypeptides having a mutated scaffold
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
IL294470B1 (en) 2013-12-12 2024-08-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
CA2939626C (en) * 2014-02-20 2023-01-17 Allergan, Inc. Complement component c5 antibodies
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3110423A4 (en) 2014-02-25 2017-09-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
BR112016019286B1 (en) * 2014-02-26 2024-02-20 Allergan, Inc. ANTI-C5 ANTIBODY
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
MX2016014160A (en) 2014-05-01 2017-02-16 Genentech Inc Anti-factor d antibody variants and uses thereof.
BR112016025751A2 (en) 2014-05-05 2018-01-16 Regeneron Pharma rodent, and methods for making a humanized rodent and mouse and for identifying a compound capable of modulating complement activation
PT3628680T (en) 2014-06-12 2021-10-07 Ra Pharmaceuticals Inc Modulation of complement activity
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3207132B1 (en) * 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
TR201903267T4 (en) 2014-10-15 2019-03-21 Alexion Pharma Inc Replication methods of large-scale eculizumab production cell culture.
WO2016061165A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of culturing a cell
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
SI3233921T1 (en) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
JP2018511557A (en) 2015-01-22 2018-04-26 中外製薬株式会社 Combination and use of two or more anti-C5 antibodies
RS62630B9 (en) 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulators of complement activity
TR201904903T4 (en) 2015-03-25 2019-05-21 Alexion Pharma Inc A method for measuring the protease activity of C3 and C5 convertase of the alternative complement pathway.
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3288586A1 (en) 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CN114796501A (en) 2015-06-25 2022-07-29 免疫医疗公司 Methods of treating cancer with combinations of antibodies and therapeutic agents
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
EP3328885A1 (en) 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
WO2017048495A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
WO2017062649A1 (en) 2015-10-07 2017-04-13 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates
EP3368073B1 (en) 2015-10-30 2024-05-15 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
CN108697759B (en) 2015-12-16 2022-08-02 Ra制药公司 Modulators of complement activity
WO2017104779A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN109310760A (en) 2016-06-07 2019-02-05 诺华股份有限公司 Anti- C5 antibody administration scheme
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
CA3027487A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
MY187848A (en) * 2016-06-17 2021-10-26 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
ES2902006T3 (en) 2016-06-27 2022-03-24 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
JOP20170154B1 (en) 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
US20190276524A1 (en) 2016-10-12 2019-09-12 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions and methods for treating central nervous system injury
JP7096240B2 (en) 2016-10-19 2022-07-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method for Quantifying Unbound C5 in Sample
ES2888904T3 (en) 2016-10-19 2022-01-10 Alexion Pharma Inc A method of quantifying unbound C5a in a sample
EP3532845A1 (en) 2016-10-27 2019-09-04 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
BR112019011053A2 (en) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc complement activity modulators
TW202412841A (en) 2017-01-31 2024-04-01 日商中外製藥股份有限公司 Use of anti-c5 antibody in manufacture of a pharmaceutical composition for treatment or prevention of a c5-related disease
CN110603252A (en) 2017-03-01 2019-12-20 艾其林医药公司 Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
JP7251792B2 (en) 2017-03-23 2023-04-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Anti-C5a Antibodies and Their Uses
US11112411B2 (en) 2017-03-31 2021-09-07 Alexion Pharmaceuticals, Inc. Method for simultaneous quantification of ALXN1210 and eculizumab in human serum or urine
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP7486415B2 (en) 2017-04-03 2024-05-17 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Treatment of inflammatory diseases with inhibitors of C5a activity
EP3612561A1 (en) 2017-04-19 2020-02-26 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
KR102656199B1 (en) * 2017-04-21 2024-04-09 볼루션 이뮤노 파마슈티컬스 에스에이 Coversin for the treatment of autoimmune blistering disease
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
ES2967965T3 (en) 2017-05-22 2024-05-06 Alexion Pharma Inc Dosage and administration of anti-C5 antibodies for the treatment of protein-losing enteropathy in patients
KR102576012B1 (en) 2017-07-27 2023-09-07 알렉시온 파마슈티칼스, 인코포레이티드 High Concentration Anti-C5 Antibody Formulation
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
AU2018345625A1 (en) 2017-10-04 2020-04-16 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis
AU2018354404A1 (en) 2017-10-26 2020-04-16 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
WO2019105916A1 (en) 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
EP3717004A4 (en) 2017-12-01 2021-12-01 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
SG11202012712YA (en) * 2018-06-19 2021-01-28 Atarga Llc Antibody molecules to complement component 5 and uses thereof
CR20210103A (en) 2018-08-01 2021-03-22 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (en) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (en) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
JP2022500427A (en) 2018-09-17 2022-01-04 国立大学法人京都大学 Administration of anti-C5 agents for the treatment of liver injury or liver failure
JP2022501378A (en) 2018-09-21 2022-01-06 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. Eculizumab for the treatment of neuromyelitis optica
CN112996497A (en) 2018-09-25 2021-06-18 艾其林医药公司 Morphic forms of complement factor D inhibitors
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3873602B1 (en) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
WO2020106724A1 (en) 2018-11-20 2020-05-28 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
EP3884052A1 (en) 2018-11-23 2021-09-29 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
EP3730617A1 (en) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
DK3914617T3 (en) 2019-01-25 2024-05-27 Alexion Pharma Inc DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
US20220275070A1 (en) 2019-07-31 2022-09-01 Hoffmann-La Roche Inc. Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
CN115137815A (en) 2019-07-31 2022-10-04 豪夫迈·罗氏有限公司 Dosage and administration regimen for treating or preventing C5-related diseases by using anti-C5 antibody covalenzumab
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
CN114981430A (en) 2019-08-27 2022-08-30 赛伦斯治疗有限责任公司 Nucleic acid for inhibiting C3 expression in cells
MX2022004726A (en) 2019-10-22 2022-05-13 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof.
JP2023507852A (en) 2019-12-23 2023-02-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using anti-C5 antibodies
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
CA3172421A1 (en) 2020-03-27 2021-09-30 Niels C. Riedemann Inhibitors of c5a for the treatment of corona virus infection
JP2023522208A (en) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ Methods of treating complement-mediated disorders caused by viruses
AU2021265813A1 (en) 2020-04-30 2022-11-10 Alnylam Pharmaceuticals, Inc. Complement factor B (CFB) iRNA compositions and methods of use thereof
JP2023526051A (en) 2020-05-12 2023-06-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド Use of complement factor D inhibitors alone or in combination with anti-C5 antibodies for the treatment of paroxysmal nocturnal hemoglobinuria
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
JP2023530977A (en) 2020-06-16 2023-07-20 エフ． ホフマン－ラ ロシュ アーゲー Method for Determining Antibody Free Antigen in a Sample
WO2021262329A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022012606A1 (en) * 2020-07-15 2022-01-20 Biosion Inc. Antibodies binding c5 and uses thereof
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4281472A1 (en) 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
WO2022159984A1 (en) 2021-01-22 2022-07-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
CA3230589A1 (en) 2021-09-02 2023-03-09 Sibylle DAMES Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
EP4402174A1 (en) 2021-09-17 2024-07-24 Novartis AG Methods for prevention of graft rejection in xenotransplantation
AU2022378567A1 (en) 2021-10-29 2024-04-11 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
KR20230105972A (en) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 ANTI-C3b ANTIBODY OR ANTI-C5 ANTIBODY CONJUGATED WITH ANGIOGENESIS INHIBITOR AND USE THEREOF
CN116712390B (en) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 High-concentration high-stability antibody preparation and preparation method thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4816565A (en) 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (en) 1989-07-27 1991-02-07 Goetze Otto METHOD FOR DETECTING AND / OR QUANTITATIVELY DETERMINING COMPLEMENT PEPTIDE C5A AND / OR C5ADESARG
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (en) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-binding proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2671350A1 (en) 1991-01-08 1992-07-10 Adir NOVEL BENZISOXAZOLE AND BENZISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69232669T2 (en) 1991-12-20 2003-02-27 Protein Design Labs, Inc. WITH GP11B / IIIA REACTIVE HUMAN ANTIBODIES
JP3939747B2 (en) * 1992-06-24 2007-07-04 アドプロテック・リミテッド Soluble CR1 derivative

Also Published As

Publication number Publication date
JP4294596B2 (en) 2009-07-15
KR100381128B1 (en) 2003-09-29
WO1995029697A1 (en) 1995-11-09
EP2270047A2 (en) 2011-01-05
JP2005185286A (en) 2005-07-14
JP3734266B2 (en) 2006-01-11
CA2189015A1 (en) 1995-11-09
KR100442019B1 (en) 2004-07-30
ES2336051T3 (en) 2010-04-07
CA2690298A1 (en) 1995-11-09
EP0758904A1 (en) 1997-02-26
BR9507594B8 (en) 2015-06-02
CA2189015C (en) 2010-04-13
BR9507594B1 (en) 2010-08-10
EP0758904A4 (en) 2005-04-20
EP2112165A3 (en) 2011-03-23
DK0758904T3 (en) 2010-01-18
EP2298808A1 (en) 2011-03-23
KR20040000388A (en) 2004-01-03
EP2112165A2 (en) 2009-10-28
NL300433I1 (en) 2010-03-01
US6355245B1 (en) 2002-03-12
JP5047996B2 (en) 2012-10-10
JP2006020633A (en) 2006-01-26
JP2012095650A (en) 2012-05-24
ATE448791T1 (en) 2009-12-15
EP2270046A2 (en) 2011-01-05
PT758904E (en) 2010-02-10
BR9507594A (en) 1997-09-16
EP2270047A3 (en) 2011-03-23
EP0758904B1 (en) 2009-11-18
AU2474795A (en) 1995-11-29
NL300433I2 (en) 2010-04-01
US6074642A (en) 2000-06-13
FR10C0016I2 (en) 2011-04-01
JPH10500289A (en) 1998-01-13
DE69536017D1 (en) 2009-12-31
JP2009165471A (en) 2009-07-30
EP2270046A3 (en) 2011-03-23
DE122009000075I1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
FR10C0016I1 (en)
DK0871631T3 (en) Antiparasitic marc fortines and paraherquamides
EP0605442A4 (en) Recombinant antibodies for human therapy.
PL332541A1 (en) D-olanzapin dihydrate
EP0805161A4 (en) (1-3)-beta-d-glucan-binding protein, antibody that recognizes the protein, and use of the protein and antibody
GB9419021D0 (en) Therapeutic protein
GB9410512D0 (en) Novel treatment
EP0977590A4 (en) Human monoclonal antibodies
PL313911A1 (en) Theraputic lamp
GB9411635D0 (en) Novel treatment
EP0779960A4 (en) Fuel control device, parts therefor and methods of making the same
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
EP0723458A4 (en) Immune modulation with class ii alpha-chain fragments
EP0667394A3 (en) Recombinant antibody produced by transformed Bacillus bacteria.
IL116071A0 (en) Novel toxins
EP0617244A3 (en) Air heater.
GB2305585B (en) Heat source
EP0662782A4 (en) Pp14-based therapy.
GB2300553B (en) Heat source
KR0112312Y1 (en) Pulleys
GB9314899D0 (en) Tumour-associated antigen
GB9401597D0 (en) Altered antibodies
HUP9903317A3 (en) Reconstituted human anti-hm 1.24 antibody
GB9504881D0 (en) Heat source
GB9504717D0 (en) Heat source